

• **Name:**

Heather Wakelee, MD

• **Current Position:**

Professor of Medicine, Oncology
Stanford University
Stanford, California, USA

• **Country:**

USA

• **Educational Background:**

Princeton University- AB
Johns Hopkins University - MD

• **Professional Experience:**

Faculty Member (Assistant, then Associate, the Full Professor) Stanford University
Faculty Director, Stanford Cancer Clinical Trials Office

• **Professional Organizations:**

International Association for the Study of Lung Cancer (IASLC) – Board of Directors
Eastern Cooperative Oncology Group (ECOG-ACRIN) -, co-chair of the thoracic committee,
executive committee member, and Stanford Principal Investigator
American Society of Clinical Oncology – fellow (FASCO), committee volunteer

• **Selected Main Scientific Publications:**

1. **Wakelee HA**, Chang ET, Gomez SL, Keegan THM, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW. Lung cancer incidence in never-smokers. *Journal of Clinical Oncology* Vol 25(5):472-478, 2007.
2. Chlebowski RT, Schwartz AG, **Wakelee H**, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O'Sullivan MJ, Ockene JK, Chen C, Hubbell FA; Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. *Lancet* Vol 374(9697):1243-51, 2009.
3. Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, **Wakelee HA**. Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. *J Thorac Oncol.* 10(3):500-8, 2015. PMID: 25402569.
4. Riess JW, West R, Dean M, Klimowicz AC, Neal JW, Hoang C, **Wakelee HA**. GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray. *Anticancer Res.* 35(2):669-76, 2015. PMID: 25667444.
5. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, Zhou L, Carter JN, West RB, Sledge GW Jr, Shrager JB, Loo BW Jr, Neal JW, **Wakelee HA**, Diehn M, Alizadeh AA. Integrated digital error suppression for improved detection of circulating tumor DNA. *Nat Biotechnol.* 2016 May;34(5):547-55. PMID: 27018799
6. Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, **Wakelee HA**, Neal JW, Alizadeh AA, Diehn M. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun.* 2016 Jun 10;7:11815. PMID: 27283993



7. Neal JW, Dahlberg SE, **Wakelee HA**, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN 1512 Investigators. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. *Lancet Oncol.* 2016 Nov 4. pii: S1470-2045(16)30561-7. PMID: 27825638
8. **Wakelee HA**, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, Leach J, Wax M, Yaron Y, Miles DR, Lara PN Jr. A phase b/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. *Cancer Chemother Pharmacol.* 2017 May;79(5):923-932.. Epub 2017 Mar 28. PMID: 28352985
9. Han SS, Rivera GA, Tammemägi MC, Plevritis SK, Gomez SL, Cheng I, **Wakelee HA**. Risk Stratification for Second Primary Lung Cancer. *J Clin Oncol.* 2017 Sep 1;35(25):2893-2899. Epub 2017 Jun 23. PMID: 28644772
10. Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, **Wakelee HA**, Loo BW Jr, Alizadeh AA, Diehn M. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. *Cancer Discov.* 2017 Dec;7(12):1394-1403. Epub 2017 Sep 24. PMID: 28899864
11. **Wakelee HA**, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol.* 2017 Dec;18(12):1610-1623. Epub 2017 Nov 9. PMID: 29129443
12. Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, **Wakelee HA**, Badve SS. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. *J Thorac Oncol.* 2018 Mar;13(3):436-446. Epub 2017 Nov 27. PMID: 29191778
13. Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, **Wakelee HA**, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC. A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. *Clin Cancer Res.* 2018 Apr 1;24(7):1525-1535. Epub 2017 Dec 4. PMID: 29203590
14. Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, **Wakelee HA**. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. *Clin Cancer Res.* 2018 Jun 15;24(12):2771-2779. Epub 2018 Mar 21. PMID: 29563138
15. Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, **Wakelee HA**, Aoki R, Pegram MD, Padda SK. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. *J Clin Oncol.* 2019 Feb 27;JCO1802018. [Epub ahead of print] PMID: 30811285